← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Alkeus Pharmaceuticals, Inc.
Somerville, MA
$4,417,738
Total funding
4
Grants
Funding over time
peak $1.3M · FY2012–23$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,251,754 · 2
FDA$2,165,984 · 2
By mechanism
R01$2,165,984 · 2
R44$2,086,555 · 1
R41$165,199 · 1
Investigators at Alkeus Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
A Phase 2a clinical trial of ALK-001 in geographic atrophy$1,054,287
R44 · FY2016 · EY
A Phase 2a clinical trial of ALK-001 in geographic atrophy$1,032,268
R44 · FY2017 · EY
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)$500,000
R01 · FY2023 · FD
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)$500,000
R01 · FY2019 · FD
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)$500,000
R01 · FY2021 · FD
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)$250,000
R01 · FY2018 · FD
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)$249,112
R01 · FY2017 · FD
Phase 1 Study of ALK001 for Stargardt Disease$166,872
R01 · FY2013 · FD
Phase 1 Safety and Pharmacokinetics of ALK001 in people over 60$165,199
R41 · FY2012 · EY